news
XELJANZ® approved in Japan for the treatment of adults with rheumatoid arthritis
25 March 2013 | By Pfizer
“RA is a serious and disabling disease and there is a need for new treatment options..."
List view / Grid view
Pfizer
news
New trial results support treatment with Inspra within first 24 hours of symptoms in patients with acute STEMI without heart failure
10 March 2013 | By Pfizer
Results from the REMINDER trial...
news
Pfizer presents Phase 3 safety and immunogenicity data on Prevnar 13® in adults with HIV
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
webinar
Leveraging cutting-edge Rapid Microbiological Methods to gain a comprehensive understanding of your environment and a competitive advantage
5 February 2013 | By Abzil BioVigilant
This webinar offers insight from both an end user and a supplier in order to share with you compelling reasons to consider the use of RMMs to gain a better understanding of your environment while improving your competitive advantage...
news
Pfizer receives FDA approval for the use of Prevnar 13
25 January 2013 | By Pfizer
Prevnar 13 is the first and only pneumococcal conjugate vaccine approved for this age group...
news
Pfizer announces top-line efficacy results from a Phase 4 study of PRISTIQ® (desvenlafaxine)
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
news
Pfizer partnership organizations significantly benefit from Pfizer’s Global Health Fellows Program
22 January 2013 | By Pfizer
Pfizer celebrates 10th anniversary of this signature social investment program...
news
Pfizer’s Bosutinib receives positive opinion
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
news
Pfizer announces availability of Quillivant XR™ CII for extended-release oral suspension in the United States
14 January 2013 | By Pfizer
Quillivant XR™ CII for extended-release oral suspension is now available...
news
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...
news
U.S. FDA Approves ELIQUIS® (apixaban)
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
news
ELIQUIS® (apixaban) approved in Japan
26 December 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb and Pfizer Inc. announced that the Japanese Ministry of Health, Labor and Welfare has approved ELIQUIS® (apixaban)...
article
Intelligent Process Condition Monitoring for industrial tablet coating operation
18 December 2012 | By Jun Huang, Saly Romero-Torres, Liam Ryan and Mojgan Moshgbar, Pfizer Inc
This paper presents a feasibility study to develop an Intelligent Process Condition Monitoring (IPCM) system for providing a real time ‘health check’ for the tablet coating process in drug product manufacturing. The study fits well under the framework of Intelligent based Manufacturing (IbM) initiated at Pfizer, and intends to move…
news
ELIQUIS® (apixaban) demonstrated superiority in reducing a composite of recurrent venous thromboembolism and all-cause death without increasing the rate of major bleeding versus placebo during one year of extended treatment
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
news
Pfizer Acquires NextWave Pharmaceuticals, Inc.
28 November 2012 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc..
